ABSTRACTS 22ND ANNUAL CONFERENCE–2014

Vira

lHep

atitis

genotype 2, 3 and 4 HEV sequences was even lower, being68.4%-74.6%, 61.1%-70.3% and 58.6%-68.2%, respectivelyfor ORF1 region, and 70.4%-73.8%, 66.3%-72.4% and65.6%-68.2%, respectively for ORF2 segment.Conclusion: All the HEV isolates from patients with acutehepatitis E from northern and eastern parts of India be-longed to genotype 1a, indicating that other HEV geno-types either do not or only rarely cause infection amonghumans in these geographical areas.

Corresponding author: Rakesh Aggarwal.Email: aggarwal.ra@gmail.com

DISTRIBUTIONOF IL28BGENOTYPEAMONGINDIAN HEALTHY AND CHRONICHEPATITIS C PATIENTS AND ITS EFFECT ONVIROLOGICAL RESPONSE TOANTIVIRAL THERAPY

Baibaswata Nayak, N. A. Shalimar, Chandreswar Prasad,Krishnendu Mondol, Jyotish Kumar Jha, Anand Kumar,Shyam Praksah, Subrat Kumar Acharya

Department of Gastroenterology, All India Institute of MedicalSciences, Ansari Nagar, New Delhi, India

Background and Objectives: Genome wide associationstudy (GWAS) indicated association of IL28b gene singlenucleotide polymorphisms (SNP) with sustained viralresponse (SVR) to IFN/RBV therapy in chronic hepatitisC (CHC) patients. But therapeutic response may vary de-pending upon ethnic populations and HCV genotype.Therefore, IL28b SNP (rs12979860C/T and rs8099917T/G) genotypes frequency, distribution in Indian healthyand CHC patient population and its association with dis-ease and virological response to IFN/RBV therapy werestudied.Methods: SNP genotyping was carried out by ARMS realtime PCR and primer extension method. Test for deviationfrom Hardy Weinberg equilibrium (HWE), frequency dis-tribution and association were carried by chi square test.Results: The distributions of SNP rs12979860C/T geno-type CC is 55.69%, 63.76%; CT is 35.61%, 44.68% and TTis 5.69%, 7.76% and distributions SNP rs8099917T/G ge-notype TT is 63.9%, 77.65%, GT is 27.21%, 33.69% andGG is 2.9% and 3.65% in Indian healthy (n = 97) andCHC (n = 116) patients. The minor allele (T) frequencyfor SNP rs12979860C/T is 0.242 and 0.259; and minorallele (G) frequency for SNP rs8099917T/G is 0.176 and0.178 between healthy (HS) and CHC patient populationrespectively. Test of deviation from HWE is not significantor HWE is consistent for rs8099917 CHC patient andrs12979860 CHC and healthy subjects but it is significantfor rs8099917 controls (Chi-square test p value is 0.67,0.54,

S26

0.46 and 0.02 respectively). Period of therapy to achieveRVR, EVR, ETVR and SVR is completed in 109, 107, 87and 51 patients, respectively in this cohort of CHC patients[n = 116, HCV genotype 1(n = 24), 2 (n = 3) and 3 (n = 89)].Association of IL28b SNP genotypes (rs12979860 CC, CT,TT and rs8099917 TT, GT and GG) for favorable virolog-ical response to antiviral therapy found significant withChi-square test P value 0.0016(RVR), 0.003(EVR),0.008(ETVR) and 0.05(SVR) for SNP rs12979860 and Chisquare test P value < 0.0001 (RVR), < 0.0001 (EVR),0.0006 (ETVR) and 0.046 (SVR) for SNP rs809991.Conclusion: The IL28b genotypes associated with favor-able response to therapy is predominant in Indian popula-tion and association of both SNP genotypes for virologicalresponse is found significant.

Corresponding author: Baibaswata Nayak.Email: baibaswata@yahoo.com

A STUDY OF SEROPREVALENCE OFHEPATITIS E IN PATIENTS WITH CIRRHOSIS

Goldie Longjam, P. N. Rao, D. N. Reddy, Manu Tandan

Department of Medical Gastroenterology, Asian Institute ofGastroenterology, Hyderabad, Andhra Pradesh, India

Introduction:HEV infection is the most frequent cause ofacute sporadic and epidemic hepatitis in India. It is a com-mon cause of acute superinfection causing acute onchronic liver failure (ACLF) in patients with chronic liverdisease (CLD). Compared to HEV infection, more than95% patients with CLD in India have protective antibodyagainst HAV and empirical vaccination of cirrhotics withHAV vaccine is not necessary in India. The seroprevalencedata of HEV in patients with cirrhosis is small, in additionto its unpredictable protective value and questionableduration of persistence of the antibodies. With the immi-nent availability of HEV vaccine in India, a question willarise whether empirical vaccination of cirrhotics with vac-cine will be cost effective.Aims and objectives: 1) To study the seroprevalence ofHepatitis E virus in subjects with cirrhosis 2) To determinethe effects of previous HEV infection on the severity of liverdisease 3) To study any possible association of hepatitis Eseropositivity with cirrhosis.Material and Methods: An observational cross-sectional analysis of serum samples for IgGhepatitis E(against antigens from ORF-2 HEV genome) in allconsecutive adult patients with cirrhosis of liver irre-spective of etiology were enrolled for one year durationand data recorded.Results: 19 patients of total 117 (16.2 %) were found to beIg G HEV positive .16/106 (15.1%) males and 27.3 % (3/11)females were positive. However, no statistical difference

© 2014, INASL